Phage therapy for drug-resistant pneumonia in ventilated patients
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether a cocktail of bacteriophages (viruses that kill bacteria) can treat ventilator-associated pneumonia caused by hard-to-treat bacteria like Klebsiella, Acinetobacter, or Pseudomonas. It may help patients who have not responded to standard antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pneumonia from being on a ventilator.
- Your infection is caused by Klebsiella, Acinetobacter, or Pseudomonas bacteria that are resistant to multiple drugs.
- You are between 18 and 85 years old.
- You or your legal guardian can give written permission to participate.
- You are not pregnant or breastfeeding.
- Your oxygen needs are low to moderate and your blood pressure is stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doctors can safely reduce or stop some antibiotics earlier for patients on breathing machines who develop pneumonia in the ICU. It looks at using lab results to guide treatment, which might lower side effects from unnecessary antibiotics.
This trial tests whether using a fast respiratory test combined with a treatment plan can help doctors choose the right antibiotics sooner for patients in the intensive care unit who get pneumonia from a breathing machine. It aims to improve treatment and reduce unnecessary antibiotics.
This trial tests an “antibiotic stewardship” approach—choosing and adjusting antibiotics in a smarter way—for a first episode of pneumonia in patients on a breathing machine. It may help ensure the right antibiotics are used at the right time, while avoiding unnecessary or overly broad treatment.
This trial tests whether bacteriophages—viruses that kill bacteria—can help treat a chronic lung infection caused by a drug-resistant bacterium called Mycobacterium abscessus.
This early-stage trial tests a combination of a traditional Chinese herbal formula and bacteriophages (viruses that kill bacteria) to treat severe pneumonia caused by drug-resistant bacteria. The treatment is inhaled directly into the lungs and may help when standard antibiotics don't work.
This trial tests whether adding a special virus (bacteriophage) that kills antibiotic-resistant bacteria to standard IV antibiotics is safe for people with cystic fibrosis. It is for adults whose lung infections are hard to treat because the bacteria have stopped responding to usual antibiotics.
Hear when a new VAP - Ventilator Associated Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.